Orca Bio's TREGZI Shows Three-Year Survival Benefit in Blood Cancer Transplants
Event summary
- Orca Bio published three-year overall survival data for TREGZI in hematologic malignancies, showing a 83% survival rate vs. 66% for PTCy.
- The retrospective analysis compared TREGZI + tacrolimus to a CIBMTR-NMDP registry cohort using PTCy-based GVHD prophylaxis.
- TREGZI demonstrated a hazard ratio of 0.41 (p=0.003) for overall survival compared to PTCy.
- The study was published in Transplantation and Cellular Therapy on September 17, 2026.
The big picture
Orca Bio's data reinforces the shift from traditional GVHD prevention methods like tacrolimus/methotrexate to more targeted cell therapies. The results position TREGZI as a potential new standard in allogeneic stem cell transplants, addressing a critical unmet need in blood cancer treatment. The publication in a peer-reviewed journal lends credibility to Orca Bio's technology platform, which aims to redefine immune system restoration in transplant patients.
What we're watching
- Market Adoption
- Whether TREGZI can gain broader adoption as a standard of care in allogeneic stem cell transplants.
- Competitive Positioning
- How Orca Bio positions TREGZI against emerging GVHD prevention therapies.
- Long-Term Efficacy
- The durability of TREGZI's survival benefits beyond the three-year mark.
Related topics